Loading
A phase 3 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by ArriVent BioPharma, Inc., now recruiting.
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations is a phase 3 interventional study registered as NCT07185997 by ArriVent BioPharma, Inc., with 480 participants planned, started 2025-12-17 and due to reach its primary completion in 2029-02. Interventions recorded: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice. Conditions listed: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing. No results are recorded here; the registry entry is the source.
Shares ArriVent BioPharma, Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Furmonertinib, Small-cell lung cancer, Non-small-cell lung cancer.